Corisella inscripta

BEDOUKIAN RESEARCH INC. PARTNERS WITH INSCRIPTA TO SUSTAINABLY DEVELOP AND MANUFACTURE NATURALLY PRODUCED INGREDIENTS

Retrieved on: 
Wednesday, July 19, 2023
Nobel Prize, CRISPR, BRI, Partnership, Corisella inscripta, Risk, Fine chemical, Renewable energy

The partnership aims to deliver naturally produced products with superior quality and consistency, while reducing the environmental footprint associated with traditional chemical manufacturing processes and providing affordable, sustainable and safe solutions.

Key Points: 
  • The partnership aims to deliver naturally produced products with superior quality and consistency, while reducing the environmental footprint associated with traditional chemical manufacturing processes and providing affordable, sustainable and safe solutions.
  • Inscripta's GenoScaler™ is a novel and proprietary ultra-high-throughput, CRISPR-enabled strain engineering platform designed to rapidly optimize microbial strains with vastly improved traits and productivities.
  • Inscripta will employ GenoScaler™ to efficiently develop high-yield strains to manufacture and provide BRI with sustainable ingredients.
  • R&D teams at Inscripta are developing sustainable biomanufacturing processes through accelerated strain engineering and process development for these ingredients.

Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments

Retrieved on: 
Monday, April 24, 2023
Semiconductor, Health, Technology, Health Technology, Genetics, Pharmaceutical, Biotechnology, Hamamatsu Photonics, Pacific Biosciences, Reagent, Operation, Protein sequencing, Senior, Data science, Marketing, Chief commercial officer, Algorithm, Autocar Sales and Service Building, University of California, Santa Cruz, Oxford Nanoimaging, Research, Genomics, Dicarboxylic acid, Doctor of Philosophy, Proteomics, Protein, UC, Engineering, Epic Sciences, Raytheon Technologies, Drug discovery, Supply, Corisella inscripta, Genetix, Platinum, Management, Fine chemical, Illumina

These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si's growing customer base and further scaling of the company.

Key Points: 
  • These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si's growing customer base and further scaling of the company.
  • Prior to this, Ms. Atkinson held executive leadership positions at Truvian, Epic Sciences, Edico Genome and Illumina.
  • Mr. Hutcheson has more than 20 years of experience as a commercial professional within the genomics, biotechnology, and drug discovery markets.
  • Its elegant simplicity enables broad-scale access to proteomic data, making it a critical instrument for the future of proteomics research.

KALSEC® PARTNERS WITH INFINOME™ BIOSCIENCES TO SUSTAINABLY DEVELOP AND MANUFACTURE PRECISION FERMENTATION PRODUCTS

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Risk, CA, Technology, Agriculture, Knowledge, Environment, Taste, Food, Corisella inscripta, Partnership, CRISPR, Solution, Efficiency, Renewable energy, Fine chemical

Infinome will employ GenoScaler to develop ingredient-producing strains and provide Kalsec with these ingredients to validate their performance in food applications.

Key Points: 
  • Infinome will employ GenoScaler to develop ingredient-producing strains and provide Kalsec with these ingredients to validate their performance in food applications.
  • R&D teams at Infinome will work with Kalsec to develop sustainable biomanufacturing processes through accelerated strain engineering and process development.
  • Through advanced technology, strategy, and processes, we are helping to create sustainable solutions with long-term partners like Kalsec."
  • Infinome Biosciences is developing cost-effective, sustainable solutions for a variety of biomanufacturing applications including food, feed, agriculture, chemicals, and pharmaceuticals.

ALDEVRON LICENSES THE MANUFACTURING OF A TYPE-V CRISPR NUCLEASE FROM INSCRIPTA

Retrieved on: 
Monday, May 16, 2022
B cell, DNA, Software, Plant, GMP, Enzyme, IPSC, Vaccine, Research, Onyx, Industry, Partnership, Time, CRISPR, Program, RNA, Protein, CEO, Corisella inscripta

FARGO, N.D. , May 16, 2022 /PRNewswire/ --Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, along with Inscripta, a life science technology company dedicated to making CRISPR-based genome engineering accessible to any research lab, announced today the signing of an agreement that provides Aldevron a license to manufacture and commercialize Eureca-V™ Nuclease, the wild-type MAD7™ CRISPR Type-V nuclease.

Key Points: 
  • This license expands access to high quality CRISPR reagents, enablingclients to innovate and more rapidly translate their research into breakthrough cell therapies, especially allogenic cell treatments.
  • "Eureca-V will be our third GMP CRISPR nuclease and the first Type-V nuclease available as a GMP catalog product, enabling access to a clinical-grade reagent in a fraction of the time and the cost of manufacturing a custom batch.
  • Inscripta first released the MAD7 nuclease in 2017 to both academic and commercial researchers under a unique technology access program designed to broaden access to CRISPR.
  • Inscripta supports its customers around the world from facilities in Boulder, Colorado; San Diego and Pleasanton, California; and Copenhagen, Denmark.